Cereno Scientific will conduct a clinical study using Data MATRIX software

Cereno Scientific will conduct a clinical study using Data MATRIX software

Data MATRIX has been selected by a Swedish biotechnology company Cereno Scientific to provide support in terms of Data Management and Biostatistics for their upcoming phase II study in patients after knee replacement surgery.

Study data will be collected using MATRIX EDC/IWRS application, which is a proprietary fully validated Data MATRIX software.

"We would like to thank Cereno Scientific for their trust. MATRIX EDC/IWRS is a reliable data collection platform, which already proved its worth, and we are sure that it perfectly matches the Sponsor’s project requirements. Users from Europe, Russia and the US provided highly positive feedback about system usability, work speed and our user-friendly interface”, – Diana Mesropian, COO Data MATRIX.

Cereno Scientific has previously signed a Letter of Intent with OCT about a collaboration to conduct this phase II study. The President of OCT speaks positively about the choice of Data MATRIX as a vendor:

“For many years Data MATRIX is OCT’s preferred vendor for EDC, data management and biostatistics services. Based on our experience, we are convinced that all activities will be performed by experienced professionals who adjust and validate software before the start of the project taking into account all aspects of the study”, – Dmitry Sharov, President OCT.

Data MATRIX team will be responsible for the following activities within the study: CRF Development, EDC Database Design and Setup, IWRS Deployment and Validation, Statistical Analysis and Report.



About Cereno Scientific AB 

Cereno Scientific is developing a novel preventive medicine to treat thrombosis-related disease, based on the body’s own intelligent clot-busting system. Cardiovascular disease is currently the leading cause of death worldwide. Current therapies are connected to an increased risk of bleeding and, as a result, low effectiveness due to lower dosing levels. In turn, this leads to a high risk of new blood clots. Cereno Scientific’s drug candidate, CS1, is expected to provide a possibility for an effective prevention of thrombosis and a lower risk for serious bleeding complications than with current blood-thinning therapies. CS1 is a controlled release formulation of a known compound and, as such, is expected to have a relatively short development time. The Gothenburg-based company is located in AstraZeneca’s BioVentureHub and is supported by GU Ventures. Cereno Scientific’s B share has been listed on Spotlight Stock Market since June 2016 with the ticker CRNO B, ISIN SE0008241558.